Cardinal Health (CAH)
(Delayed Data from NYSE)
$111.93 USD
-0.62 (-0.55%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $111.94 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.93 USD
-0.62 (-0.55%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $111.94 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Zacks News
Fresenius Medical (FMS) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter revenues benefit from strong performances across all segments, especially the North America and Asia-Pacific regions. However, rising costs hurt margins.
Masimo (MASI) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q1 sales.
DaVita (DVA) Tops Q1 Earnings Estimates, Ups FY23 EPS View
by Zacks Equity Research
DaVita's (DVA) robust revenues in both segments drive its first-quarter performance.
Shockwave Medical (SWAV) Q1 Earnings Top, Revenues Surge Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
McKesson (MCK) Q4 Earnings Beat Estimates, U.S. Sales Strong
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2023 results benefit from growth in the United States. Divestment hurt the International segment.
Avanos (AVNS) Q1 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Despite strength in Avanos' (AVNS) Chronic Care segment, its overall first-quarter results reflect soft performances.
AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall Q1 performance.
Inogen (INGN) Q1 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall first-quarter results reflect soft performances.
Should Value Investors Buy AmerisourceBergen (ABC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal Health (CAH) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results benefit from the Pharmaceutical segment's solid performance.
Cardinal Health (CAH) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 17.57% and 1.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q2 sales.
2 Medical Stocks to Buy Before Earnings
by Shaun Pruitt
Cardinal Health (CAH) and Ligand Pharmaceuticals (LGND) are two healthcare companies that investors certainly want to watch going into their quarterly reports.
What Awaits Lantheus Holdings (LNTH) This Earnings Season?
by Zacks Equity Research
Lantheus Holdings' (LNTH) first-quarter results are likely to reflect solid top-line results on the back of robust product adoption.
Is a Beat Likely for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) third-quarter fiscal 2023 results are expected to reflect solid performance in the Pharmaceutical segment. However, inflationary pressure is likely to have continued.
Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply
by Zacks Equity Research
Autolus (AUTL) partners with Cardinal Health to bring next-generation CAR-T cell therapies to the market and revolutionize cancer treatment.
McKesson (MCK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $82.10 in the latest trading session, marking a +0.02% move from the prior day.
Cardinal (CAH) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
AMN Healthcare (AMN) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) first-quarter results are likely to reflect soft demand across its segments.
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Merit Medical Systems, Inc. (MMSI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cardinal Health (CAH) closed at $80.08, marking a -0.01% move from the previous day.